Reference
1. Organization WH. The molecular genetic epidemiology of Cystic Fibrosis : report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS. Genoa, Italy - 19 june 20022004.
2. Stephenson AL, Tom M, Berthiaume Y, Singer LG, Aaron SD, Whitmore GA, et al. A contemporary survival analysis of individuals with cystic fibrosis: a cohort study. Eur Respir J. 2015;45(3):670-9.
3. Mehta G, Macek M, Mehta A, Group ERW. Cystic fibrosis across Europe: EuroCareCF analysis of demographic data from 35 countries. J Cyst Fibros. 2010;9 Suppl 2:S5-S21.
4. Salvatore D, Buzzetti R, Mastella G. Update of literature from cystic fibrosis registries 2012-2015. Part 6: Epidemiology, nutrition and complications. Pediatr Pulmonol. 2017;52(3):390-8.
5. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161(4):233-41.
6. Lai HJ, Cheng Y, Cho H, Kosorok MR, Farrell PM. Association between initial disease presentation, lung disease outcomes, and survival in patients with cystic fibrosis. Am J Epidemiol. 2004;159(6):537-46.
7. Yen EH, Quinton H, Borowitz D. Better nutritional status in early childhood is associated with improved clinical outcomes and survival in patients with cystic fibrosis. J Pediatr. 2013;162(3):530-5.e1.
8. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34(2):91-100.
9. Blanchard AC, Waters VJ. Microbiology of Cystic Fibrosis Airway Disease. Semin Respir Crit Care Med. 2019;40(6):727-36.
10. O’Shea D, O’Connell J. Cystic fibrosis related diabetes. Curr Diab Rep. 2014;14(8):511.
11. Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI. Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care. 2010;33(2):311-6.
12. Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W. Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care. 2009;32(9):1626-31.
13. Barr HL, Britton J, Smyth AR, Fogarty AW. Association between socioeconomic status, sex, and age at death from cystic fibrosis in England and Wales (1959 to 2008): cross sectional study. BMJ. 2011;343:d4662.
14. Waters V, Ratjen F. Pulmonary Exacerbations in Children with Cystic Fibrosis. Ann Am Thorac Soc. 2015;12 Suppl 2:S200-6.
15. Harness-Brumley CL, Elliott AC, Rosenbluth DB, Raghavan D, Jain R. Gender differences in outcomes of patients with cystic fibrosis. J Womens Health (Larchmt). 2014;23(12):1012-20.
16. H. L-R. Los niveles socioeconómicos en México y la distribución del gasto. 2009.
17. Lee TW, Brownlee KG, Conway SP, Denton M, Littlewood JM. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros. 2003;2(1):29-34.
18. Gómez Dantés O, Sesma S, Becerril VM, Knaul FM, Arreola H, Frenk J. [The health system of Mexico]. Salud Publica Mex. 2011;53 Suppl 2:s220-32.
19. Keogh RH, Stanojevic S. A guide to interpreting estimated median age of survival in cystic fibrosis patient registry reports. J Cyst Fibros. 2018;17(2):213-7.
20. Foundation CF. 2019 Cystic fibrosis Foundation Patient Registry Highlights. 2019.
21. Kerem E, Cohen-Cymberknoh M. Disparities in Cystic Fibrosis Care and Outcome: Socioeconomic Status and Beyond. Chest. 2016;149(2):298-300.
22. Schechter MS, Shelton BJ, Margolis PA, Fitzsimmons SC. The association of socioeconomic status with outcomes in cystic fibrosis patients in the United States. Am J Respir Crit Care Med. 2001;163(6):1331-7.
23. Schechter MS, McColley SA, Silva S, Haselkorn T, Konstan MW, Wagener JS, et al. Association of socioeconomic status with the use of chronic therapies and healthcare utilization in children with cystic fibrosis. J Pediatr. 2009;155(5):634-9.e1-4.
24. O’Connor GT, Quinton HB, Kneeland T, Kahn R, Lever T, Maddock J, et al. Median household income and mortality rate in cystic fibrosis. Pediatrics. 2003;111(4 Pt 1):e333-9.
25. Taylor-Robinson DC, Thielen K, Pressler T, Olesen HV, Diderichsen F, Diggle PJ, et al. Low socioeconomic status is associated with worse lung function in the Danish cystic fibrosis population. Eur Respir J. 2014;44(5):1363-6.
26. Watts KD, Seshadri R, Sullivan C, McColley SA. Increased prevalence of risk factors for morbidity and mortality in the US Hispanic CF population. Pediatr Pulmonol. 2009;44(6):594-601.
27. McGarry ME, Williams WA, McColley SA. The demographics of adverse outcomes in cystic fibrosis. Pediatr Pulmonol. 2019;54 Suppl 3:S74-S83.
28. E BA. Early acquisition of Pseudomonas aeruginosa in Mexican children with cystic fibrosis. Acta Pediatr Mex; 2020. p. 159-64.
29. Sathe M, Houwen R. Meconium ileus in Cystic Fibrosis. J Cyst Fibros. 2017;16 Suppl 2:S32-S9.
30. E Y. Correlación genotipo -fenotipo en una muestra de pacientes mexicanos con fibrosis quística. Rev Invest Clin; 2013. p. 491-9.
31. Chávez-Saldaña M, Yokoyama E, Lezana JL, Carnevale A, Macías M, Vigueras RM, et al. CFTR allelic heterogeneity in Mexican patients with cystic fibrosis: implications for molecular screening. Rev Invest Clin. 2010;62(6):546-52.
32. Selvadurai HC, Blimkie CJ, Cooper PJ, Mellis CM, Van Asperen PP. Gender differences in habitual activity in children with cystic fibrosis. Arch Dis Child. 2004;89(10):928-33.
33. Zeitlin PL. Cystic fibrosis and estrogens: a perfect storm. J Clin Invest. 2008;118(12):3841-4.
34. Fogarty AW, Britton J, Clayton A, Smyth AR. Are measures of body habitus associated with mortality in cystic fibrosis? Chest. 2012;142(3):712-7.